Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
BeOne Medicines has reached a voluntary agreement with the U.S. government to expand access to cancer therapies and ramp up domestic manufacturing. The deal includes participation in the GENEROUS Medicaid pricing model and a tariff exemption tied to a $300 million manufacturing investment in New Jersey. Total U.S. manufacturing investment now exceeds $1 billion.
BeOne Medicines has announced a voluntary agreement with the U.S. government aimed at broadening access to innovative cancer treatments for American patients while deepening its domestic manufacturing presence. The deal covers two key pillars: pricing commitments and manufacturing investment.
On the pricing front, BeOne is joining the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model, pledging to price future FDA-approved products in line with other major developed markets — a move designed to make its oncology therapies more affordable for Medicaid patients. On the manufacturing side, BeOne secured an exemption from Section 232 pharmaceutical tariffs in exchange for its ongoing U.S. investment commitments, including a newly announced $300 million expansion of its Hopewell, NJ facility.
By the Numbers:
Why it matters: This agreement reflects a broader trend of pharma companies aligning with U.S. government priorities around drug pricing and domestic supply chain resilience — with real implications for Medicaid patient access to cutting-edge oncology therapies.
